



ANDA 78-883 (Amendment 1)

Mylan Pharmaceuticals, Inc.
U.S. Agent for: Matrix Laboratories Limited
Attention: Ron Groman, Director
781 Chestnut Ridge Road
P.O. Box 4310
Morgantown, WV 26504-4310

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated March 21, 2007, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Efavirenz Tablets, 600 mg.

This ANDA was reviewed under the expedited review provisions of the President's Emergency Plan for AIDS Relief (PEPFAR).

Reference is also made to the tentative approval letter issued by this office on July 12, 2007. We acknowledge receipt of your amendment dated December 13, 2007. This amendment provides for the addition of an alternate manufacturing site for the manufacture of the active ingredient, Efavirenz.

We have completed the review of this ANDA as amended on December 13, 2007, and we have concluded that your Efavirenz Tablets, 600 mg, manufactured with active ingredient made at the alternate site are drug is safe and effective for use as recommended in the submitted labeling. However, we remain unable to grant final approval to your ANDA at this time because of the patent issue noted below. Therefore, the ANDA remains **tentatively approved**. This determination is based upon information available to the agency at this time, (i.e., information in your ANDA and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacture and testing of the drug product). This determination is subject to change on the basis of new information that may come to our attention.

As previously noted in our July 12, 2007, tentative approval letter, the reference listed drug (RLD) upon which you have based your ANDA, Sustiva, Tablets, 600 mg of Bristol Myers Squibb, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") for this drug product:

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
5,519,021 (the '021 patent)	May 21, 2013
5,663,169 (the '169 patent)	September 2, 2014
5,811,423 (the '423 patent)	August 7, 2012
6,639,071 (the '071 patent)	February 14, 2018
6,939,964 (the '964 patent)	January 20, 2018

Your ANDA contains paragraph III certifications to each of these patents under section 505(j)(2)(A)(vii)(III) of the Act stating that Matrix Laboratories Limited will not market Efavirenz Tablets, 600 mg, in the U.S. prior to the expiration of these patents. Therefore, final approval of your ANDA may not be made effective pursuant to section 505(j)(5)(B)(ii) of the Act until each of the patents have expired, currently, February 14, 2018.

To reactivate your ANDA prior to final approval, please submit a "MINOR AMENDMENT - FINAL APPROVAL REQUESTED" 90 days prior to the date you believe that your ANDA will be eligible for final approval. This amendment should provide the legal/regulatory basis for your request for final approval and should include a copy of a court decision, or a settlement or licensing agreement, as appropriate. It should also identify changes, if any, in the conditions under which the ANDA was tentatively approved, i.e., updated information such as final-printed labeling, chemistry, manufacturing, and controls data as appropriate. This amendment should be submitted even if none of these changes were made, and it should be designated clearly in your cover letter as a MINOR AMENDMENT - FINAL APPROVAL REQUESTED.

In addition to the amendment requested above, the agency may request at any time prior to the date of final approval that you submit an additional amendment containing the requested information. Failure to submit either or, if requested, both amendments may result in rescission of the tentative approval

status of your ANDA, or may result in a delay in the issuance of the final approval letter.

We also note your commitment to have an Antiretroviral Pregnancy Registry in place prior to this ANDA receiving full approval.

Any significant changes in the conditions outlined in this ANDA as well as changes in the status of the manufacturing and testing facilities' compliance with current good manufacturing practices (cGMPs) are subject to agency review before final approval of the application will be made. Such changes should be categorized as representing either "major" or "minor" changes, and they will be reviewed according to OGD policy in effect at the time of receipt. The submission of multiple amendments prior to final approval may also result in a delay in the issuance of the final approval letter.

This drug product may not be marketed in the United States without final agency approval under section 505 of the Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under section 301 of the Act. Also, until the agency issues the final approval letter, this drug product will not be deemed approved for marketing under section 505 of the Act, and will not be listed in the "Orange Book." Should you believe that there are grounds for issuing the final approval letter prior to February 14, 2018, you should amend your ANDA accordingly.

For further information on the status of this ANDA or upon submitting an amendment to the ANDA, please contact Laura Longstaff, Project Manager, at 240-276-8500.

Sincerely yours,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research